Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center

BACKGROUND: Regorafenib is an oral multikinase inhibitor and became the first second-line systemic treatment for hepatocellular carcinoma (HCC) following the phase III RESORCE trial. This single-center study retrospectively analyzed the clinical data and follow-up results of patients with recurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qingwei, Rao, Wei, Huo, Junyu, Li, Zixiang, Wang, Song, Qiu, Wensheng, Guan, Ge, Xin, Yang, Fan, Ning, Cai, Jinzhen, Wu, Liqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890826/
https://www.ncbi.nlm.nih.gov/pubmed/36726082
http://dx.doi.org/10.1186/s12876-023-02661-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890826/
https://www.ncbi.nlm.nih.gov/pubmed/36726082
http://dx.doi.org/10.1186/s12876-023-02661-2

Ejemplares similares